Bactolac Pharmaceutical, Inc. – ‘10-K’ for 9/30/03 – EX-31.1

On:  Tuesday, 1/13/04, at 2:08pm ET   ·   For:  9/30/03   ·   Accession #:  1079973-4-10   ·   File #:  0-26362

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Annual Report   —   Form 10-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                         54    266K 
 2: EX-10.68(A)  First Amd to Loan and Security Agmt Dtd 12/31/03      5     21K 
 3: EX-14       Code of Ethics of Advanced Nutraceuticlas, Inc.        2±     9K 
 4: EX-21       Subsidiaries of the Company                            1      5K 
 5: EX-23.1     Consent of Grant Thornton LLP                          1      7K 
 6: EX-23.2     Consent of Gelfond Hochstadt Pangburn, P.C.            1      7K 
 7: EX-31.1     Section 302 Certification From CEO                     2±    10K 
 8: EX-31.2     Section 302 Certification From CFO                     2±    10K 
 9: EX-32       Section 906 Certifications                             1      8K 

EX-31.1   —   Section 302 Certification From CEO

                                                                    Exhibit 31.1

 CERTIFICATION

I, Gregory Pusey, President and Chief Executive Officer certify that:           

1. I have reviewed this annual report on Form 10-K of Advanced        
Nutraceuticals, Inc. (the "Registrant");                                        

     2. Based on my knowledge, this report does not contain any untrue statement
of a material fact or omit to state a material fact necessary to make the       
statements made, in light of circumstances under which such statements were     
made, not misleading with respect to the period covered by this report;         

 3. Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the Registrant as  
of, and for, the periods presented in this report.                              

 4. The Registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in  
Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Registrant [language omitted
in accordance with SEC transition instructions contained in SEC Release         
34-47986] and have:                                                             

a)   Designed such disclosure controls and procedures, or caused such 
disclosure controls and procedures to be designed under our 
    supervision, to ensure that material information relating to the
         Registrant, including its consolidated subsidiaries, is made known to
         us by others within those entities, particularly during the period in
which this report is being prepared;                        

b)   [Paragraph omitted in accordance with SEC transition instructions
contained in SEC Release 34-47986]                          

  c)   Evaluated the effectiveness of the Registrant's disclosure controls
         and procedures and presented in this report our conclusions about the
          effectiveness of the disclosure controls and procedures, as of the end
      of the period covered by this report based on such evaluation; and

d)   Disclosed in this report any change in the Registrant's internal 
          control over financial reporting that occurred during the Registrant's
         most recent fiscal quarter (the Registrant's fourth fiscal quarter in
     the case of an annual report) that has materially affected, or is
     reasonably likely to materially affect, the Registrant's internal
control over financial reporting; and                       

   5. The Registrant's other certifying officers and I have disclosed, based
on our most recent evaluation of internal control over financial reporting, to  
the Registrant's auditors and the audit committee of the Registrant's board of  
directors (or persons performing the equivalent functions):                     

    (a)  All significant deficiencies and material weaknesses in the design or
    operation of internal control over financial reporting which are
     reasonably likely to adversely affect the Registrant's ability to
    record, process, summarize and report financial information; and

    (b)  Any fraud, whether or not material, that involves management or other
      employees who have a significant role in the Registrant's internal
control over financial reporting.                           

Date:    January 12, 2004       By:  /s/ Gregory Pusey                          
                    ----------------------------
       Gregory Pusey
                               President and Chief Executive Officer

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing		Date		Other Filings
Filed on:		1/13/04
		1/12/04
For Period End:		9/30/03		10-K/A
				List all Filings